Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity. 2011

Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
Department of Medical Biochemistry and Biophysics, Umeå University, SE-90187 Umeå, Sweden.

Parkinson's disease is a common neurodegenerative disorder characterized by α-synuclein (α-Syn)-containing Lewy body formation and selective loss of dopaminergic neurons in the substantia nigra. We have demonstrated the modulating effect of noopept, a novel proline-containing dipeptide drug with nootropic and neuroprotective properties, on α-Syn oligomerization and fibrillation by using thioflavin T fluorescence, far-UV CD, and atomic force microscopy techniques. Noopept does not bind to a sterically specific site in the α-Syn molecule as revealed by heteronuclear two-dimensional NMR analysis, but due to hydrophobic interactions with toxic amyloid oligomers, it prompts their rapid sequestration into larger fibrillar amyloid aggregates. Consequently, this process rescues the cytotoxic effect of amyloid oligomers on neuroblastoma SH-SY5Y cells as demonstrated by using cell viability assays and fluorescent staining of apoptotic and necrotic cells and by assessing the level of intracellular oxidative stress. The mitigating effect of noopept against amyloid oligomeric cytotoxicity may offer additional benefits to the already well-established therapeutic functions of this new pharmaceutical.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000682 Amyloid A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease. Amyloid Fibril,Amyloid Fibrils,Amyloid Substance,Fibril, Amyloid,Fibrils, Amyloid,Substance, Amyloid
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051844 alpha-Synuclein A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection. Non-AB Component of AD Amyloid Protein,Non AB Component of AD Amyloid Protein,alpha Synuclein
D058105 Polymerization Chemical reaction in which monomeric components are combined to form POLYMERS (e.g., POLYMETHYLMETHACRYLATE). Polymerizations
D018384 Oxidative Stress A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi). Anti-oxidative Stress,Antioxidative Stress,DNA Oxidative Damage,Nitro-Oxidative Stress,Oxidative Cleavage,Oxidative DNA Damage,Oxidative Damage,Oxidative Injury,Oxidative Nitrative Stress,Oxidative Stress Injury,Oxidative and Nitrosative Stress,Stress, Oxidative,Anti oxidative Stress,Anti-oxidative Stresses,Antioxidative Stresses,Cleavage, Oxidative,DNA Damage, Oxidative,DNA Oxidative Damages,Damage, DNA Oxidative,Damage, Oxidative,Damage, Oxidative DNA,Injury, Oxidative,Injury, Oxidative Stress,Nitrative Stress, Oxidative,Nitro Oxidative Stress,Nitro-Oxidative Stresses,Oxidative Cleavages,Oxidative DNA Damages,Oxidative Damage, DNA,Oxidative Damages,Oxidative Injuries,Oxidative Nitrative Stresses,Oxidative Stress Injuries,Oxidative Stresses,Stress Injury, Oxidative,Stress, Anti-oxidative,Stress, Antioxidative,Stress, Nitro-Oxidative,Stress, Oxidative Nitrative,Stresses, Nitro-Oxidative
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective
D018697 Nootropic Agents Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. Anti-Dementia Agent,Antidementia Agent,Cognitive Enhancer,Cognitive Enhancers,Nootropic,Nootropic Agent,Nootropic Drug,Procognitive Agent,Anti-Dementia Agents,Antidementia Agents,Nootropic Drugs,Nootropics,Procognitive Agents,Agent, Anti-Dementia,Agent, Antidementia,Agent, Nootropic,Agent, Procognitive,Agents, Anti-Dementia,Agents, Antidementia,Agents, Nootropic,Agents, Procognitive,Anti Dementia Agent,Anti Dementia Agents,Drug, Nootropic,Drugs, Nootropic,Enhancer, Cognitive,Enhancers, Cognitive

Related Publications

Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
January 2002, Eksperimental'naia i klinicheskaia farmakologiia,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
January 2009, Eksperimental'naia i klinicheskaia farmakologiia,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
August 2007, Journal of psychopharmacology (Oxford, England),
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
May 2019, Food & function,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
January 2001, Methods in molecular medicine,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
January 2019, International journal of nanomedicine,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
January 2020, International journal of molecular sciences,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
February 2019, Bulletin of experimental biology and medicine,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
October 2019, Journal of agricultural and food chemistry,
Xueen Jia, and Anna L Gharibyan, and Anders Öhman, and Yonggang Liu, and Anders Olofsson, and Ludmilla A Morozova-Roche
July 2008, Bulletin of experimental biology and medicine,
Copied contents to your clipboard!